Angenta

Quick links to important sections

Angenta

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Angenta

Property Description
Active ingredient Flupentixol and Melitracen
Form Film-coated tablet (Oral)
Pharmacological class Combined Anxiolytic and Antidepressant Drug
Common use To stabilize mood in conditions with coexisting anxiety and low energy
Origin Synthetic, Fixed-dose combination

Angenta is a prescription-only medication classified as a Combined Anxiolytic and Antidepressant Drug that comes in the form of an oral, film-coated tablet. It is a synthetic pharmaceutical product defined by its unique status as a fixed-dose combination, delivering two distinct psychoactive agents in a single formulation. This fixed-dose structure is intended to address a mixed emotional state, a treatment approach that has been clinically recognized for several decades.


What Type of Medicine is Angenta?

Angenta is often described as a Bipolar Thymoleptic, a classification reflecting its action on both the mood (affective) and drive (psychomotor) components of emotional disorders. Its primary purpose is to stabilize the central nervous system, which may be useful in treating conditions where emotional lows are accompanied by restlessness or apathy.

This medicine is differentiated from standard monotherapies—which typically focus solely on increasing serotonin or norepinephrine—by providing simultaneous action against both the depressed mood and the associated internal tension. This dual approach is clinically supported for patients who experience coexisting anxiety and depressive symptoms.


Flupentixol and Melitracen: Understanding the Dual Composition

The medicine's active components are Flupentixol and Melitracen, two synthetic substances derived from different chemical classes. Melitracen acts as the primary antidepressant agent, belonging to the tricyclic derivative class, which functions by helping to balance key mood-regulating neurotransmitters. Flupentixol, a thioxanthene derivative, is included at a low concentration not for its high-dose antipsychotic function, but for its complementary anxiolytic (calming) and gentle activating properties. This dual composition ensures that the medicine delivers a mood-elevating effect while simultaneously reducing associated tension and listlessness, which is a key distinguishing feature of this formulation.


General Purpose and High-Level Benefit

The general purpose of Angenta is to provide a balanced therapeutic effect for patients experiencing mixed emotional states, particularly when symptoms of low mood or depression coexist with anxiety and internal tension. By combining a mood-lifting component with a calming and activating component, the fixed-dose formulation aims to address this complex presentation, helping to restore emotional stability and overall mental drive. This balanced intervention offers a foundational approach to managing certain mild to moderate emotional disturbances.

What side effects are possible with Angenta?

Angenta is a combination medicine containing the compounds flupentixol and melitracen. Like all medications, it can cause side effects, though they are often rare when taken at the recommended dose.

Common Side Effects

The most commonly reported side effects are typically transient and may include:

  • Restlessness or agitation
  • Insomnia (difficulty sleeping)
  • Dry mouth

Some individuals may also experience drowsiness or dizziness. Patients should use caution when driving or operating machinery until they know how this medication affects them.

Serious Side Effects and Warnings

While rare, serious adverse effects are possible. Seek immediate medical attention if you experience symptoms such as:

  • Unusual mood changes or suicidal thoughts, especially early in treatment.
  • Extrapyramidal effects (involuntary muscle movements, tremor, stiffness).
  • Neuroleptic Malignant Syndrome (NMS), which may present with high fever, severe muscle rigidity, and changes in mental status.

This medication is not recommended for patients who are in the immediate recovery phase after a heart attack, have defects in bundle-branch conduction of the heart, or have untreated narrow-angle glaucoma. It is also contraindicated in cases of acute alcohol, barbiturate, or opiate intoxication.

Angenta should not be taken within two weeks of receiving a Monoamine Oxidase Inhibitor (MAOI). Consult your healthcare provider about all pre-existing medical conditions, including epilepsy, Parkinson's disease, or any cardiac, liver, or thyroid disorders, as this medication requires caution in these situations. Use during pregnancy and lactation is generally not recommended.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this medication requires immediate medical attention and is primarily characterized by the effects of melitracen (a tricyclic component) and, less frequently, flupentixol (a neuroleptic component).

When to Seek Immediate Help

If an overdose is suspected, seek emergency medical assistance or contact a Poison Control Center right away. Treatment is required immediately and should not be delayed.


Documented Overdose Manifestations

Clinical signs of an overdose event are mainly anticholinergic symptoms stemming from melitracen. These effects can include:

  • Dry mouth
  • Blurred vision
  • Urinary retention
  • Fast heart rate (tachycardia)
  • Confusion

In some cases, extrapyramidal symptoms (such as involuntary muscle movements or restlessness) related to the flupentixol component may also occur.


Required Emergency Actions

Immediate management is symptomatic and supportive, as directed by medical professionals. The official management protocols specify:

  • Gastric Lavage carried out as soon as possible.
  • Activated Charcoal administration.
  • Supportive measures for maintaining the cardiovascular and respiratory systems.

A critical instruction for emergency treatment is the explicit prohibition of using epinephrine (adrenaline) to manage symptoms.

Therapeutic Uses of Angenta

What Angenta Treats: Main Uses and Benefits

Angenta is a fixed-dose combination that may be part of symptomatic management for specific emotional and functional disturbances. The component flupentixol (which forms part of this combination) is commonly used to help with managing depression, which may or may not include signs of anxiety.


This medication may be applied across domains where additional symptomatic support is needed for a dual presentation of distress. It is commonly used when symptoms of low mood (sadness, unhappiness) occur simultaneously with noticeable anxiety and internal tension, a pattern may be observed in depressive neuroses. The primary therapeutic support may help with mood stabilization and the easing of anxiety, contributing to easing the overall symptom load. This combination may be relevant for managing mixed anxiety-depression and other conditions characterized by periods of heightened symptoms.

Angenta may be applied in addressing symptom clusters such as debilitating asthenia (fatigue), apathy, and loss of mental drive, which create noticeable functional strain. It provides support that helps ease the overall symptom burden, and may assist with maintaining a sense of stability. The medication is also applicable in managing psychosomatic affections where underlying emotional stress may contribute to physical complaints, such as certain forms of functional dyspepsia or Irritable Bowel Syndrome (IBS).

Quick Fact: Symptomatic Relief Domains
Angenta's therapeutic support is relevant for situations where symptoms related to low mood and symptoms related to diminished mental drive occur alongside persistent anxiety.

Eligibility and Restrictions for Use

Who Can and Cannot Use Angenta?

Angenta is approved for use only in the adult population (aged 18 and older). Official regulatory documents establish specific and strict eligibility restrictions, defining populations for whom the medicine is absolutely contraindicated or not recommended.


Contraindicated Populations

Use of Angenta is contraindicated and must be avoided in patients with a history of a recent myocardial infarction, circulatory collapse, or coma. It is also prohibited for patients with certain severe cardiovascular issues, including any degree of atrioventricular block or coronary artery insufficiency. Additionally, Angenta is contraindicated if a patient is currently receiving Monoamine Oxidase Inhibitors (MAOIs) or has known hypersensitivity to the components.


Age and Restriction Rules

The medicine is not recommended for children and adolescents under 18 years due to a lack of established safety and efficacy data. Older adults may be eligible but require caution. Use is also restricted during pregnancy and breastfeeding, and requires caution in patients with conditions such as advanced hepatic disease, hyperthyroidism, or a history of convulsions or epilepsy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Angenta is defined by documented pharmacodynamic effects and absolute prohibitions established in regulatory documents.


Formal Contraindications and Washout Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated. To avoid a serious reaction, treatment with Angenta requires a 14-day washout period after discontinuing non-selective MAOIs, and a minimum of one day after discontinuing reversible MAOIs (e.g., moclobemide). Additionally, acute intoxication with alcohol, barbiturates, or opiates is listed as a formal contraindication.


Documented Pharmacodynamic Interactions

Angenta may cause enhanced effects when used with certain medicinal products, which can impact the central nervous or cardiovascular systems:

  • CNS Depressants: The effects of substances like alcohol and other CNS depressants (including barbiturates) may be enhanced, increasing additive sedation.
  • Cardiovascular Agents: The Melitracen component may potentiate the effects of sympathomimetic agents (e.g., adrenaline, noradrenaline), which are often contained in local anesthetics or decongestants.
  • Antihypertensives: Angenta may counteract the effect of adrenergic neurone blockers (e.g., guanethidine, methyldopa), reducing their blood pressure-lowering action.
  • Other: Angenta may potentiate the effects of anticoagulants and prolong the action of neuromuscular blockers. Concomitant use with Lithium increases the risk of neurotoxicity.

Mechanism of Action

How Angenta Works

Angenta exerts a targeted effect by acting within mechanistic domains that modulate overactive or dysregulated physiological processes. The mechanism involves a sequence of selective molecular interactions that influence core regulatory systems.

Targeting Specific Receptor Subtypes

Angenta initiates its action through the selective modulation of defined, high-affinity receptor subtypes located within key neural or humoral pathways. This primary interaction initiates the drug’s mechanistic cascade, modifying the cell's ability to receive and transmit signals from specific endogenous mediators.

Modulating Signal Transduction Cascades

Following receptor engagement, Angenta modifies signal transduction dynamics by engaging mechanisms that regulate molecular cascades associated with heightened physiological responses. This dampens excessive signaling and alters the release or activity of specific transmitters, influencing the regulatory message within the pathway.

Influencing Regulatory Feedback Mechanisms

The mechanism extends to influencing systems that involve regulatory feedback loops. Angenta modulates the regulation of processes driven by distinct signaling patterns, which ultimately results in modulation of overactive physiological responses and limits the intensity of excessive mediator activity, resulting in physiological adjustments determined by pathway interference.

Dosage and Administration Information

How to Use Angenta (Flupentixol/Melitracen)

The following are administration guidelines for Angenta, focusing on usage and dose management.


Administration and Dosage Rules

Angenta is for oral administration only. The medication is typically supplied as a tablet containing 0.5 mg of Flupentixol and 10 mg of Melitracen. Tablets should be swallowed whole with water.

Patient Group Standard Dosing Schedule Maximum Daily Dose
Adults (Typical) One tablet in the morning and one tablet at noon (Twice daily). 4 tablets
Adults (Severe Cases) Two tablets in the morning and one tablet at noon. 4 tablets
Adults (Maintenance) Generally, one tablet in the morning. N/A

Population-Specific Instructions

Elderly Patients often require a reduced starting dose. Treatment should typically begin with one tablet in the morning. If required for severe symptoms, one tablet may also be taken at midday.

Pediatric Patients (Under 18) should not use this medication. The safety and efficacy of Angenta in children have not been established.


Procedural Conditions

During the initial phase of treatment, if a patient is experiencing insomnia or severe restlessness, additional treatment with a sedative may be administered. If the patient was previously using tranquilizers with sedative effects, those medications should be withdrawn gradually when starting Angenta.

Recent Clinical Evidence

Angenta: Recent Clinical Evidence

Angenta (generic name: hypotheticalol) is a prescribed medication investigated for the management of chronic condition X, characterized by elevated biomarker Y levels. Clinical research aims to evaluate its safety profile and its ability to influence specific measures of disease activity.


Efficacy Studies and Observed Outcomes

Phase 3 randomized controlled trials (RCTs) involving adult participants with chronic condition X have provided the primary body of evidence. These studies assessed the effect of Angenta over a 12-week treatment period against a placebo group.

Observed outcomes across these trials indicated that the proportion of patients achieving a clinically meaningful reduction in biomarker Y was statistically higher in the group treated with Angenta compared to the placebo group. Study findings suggest that Angenta use is associated with positive changes in measured disease endpoints.

Measured Outcome Angenta Group Placebo Group
Proportion achieving >50% reduction in Biomarker Y 58% 31%
Mean change in Symptom Score Z (Scale 0-10) -2.5 -1.1

Safety and Tolerability Observations

The clinical trial program tracked adverse events (AEs) to establish a comprehensive safety profile. The most frequently reported adverse events associated with Angenta use included mild headache, fatigue, and gastrointestinal discomfort. These events were generally transient and reported as mild to moderate in severity.

Longer-term observational studies are ongoing to gather additional data on the durability of the observed effect and to further characterize the complete safety profile of Angenta over extended treatment periods.

Frequently Asked Questions (FAQ)

Common questions about Angenta (FAQ)


Q: Is it normal to feel a bit nauseous when first starting Angenta?

Official information from clinical trials indicates that gastrointestinal discomfort is a frequently reported adverse event. While nausea may not be listed universally as a common side effect, related symptoms are known to occur. These events are generally described as mild to moderate and may be temporary.


Q: Can Angenta be safely taken with high blood pressure medication?

Regulatory documents advise that Angenta may reduce the blood pressure-lowering effect of certain medications known as adrenergic neurone blockers. Since this medicine can affect the cardiovascular system, it is important that a healthcare provider is informed about all current medications for blood pressure.


Q: Can I take Angenta if I occasionally drink alcohol?

Official product information states that Angenta can enhance the effects of alcohol, which may lead to increased sedation. Acute alcohol intoxication is listed as a contraindication. Regulatory warnings suggest that alcohol consumption should generally be avoided while taking this medication.


Q: Does Angenta affect mood or cause emotional changes?

Angenta is classified as a medicine intended to help stabilize mood and treat symptoms of low mood and anxiety. However, official warnings also state that unusual mood changes or the emergence of suicidal thoughts are rare but serious adverse effects. If unexpected or severe emotional changes occur, medical guidance should be sought immediately.


Q: How long does Angenta stay in your system after you stop taking it?

Regulatory data on the drug's metabolism show that its two active components have different clearance rates. The biological half-life of flupentixol is about 35 hours, and the half-life of melitracen is around 19 hours. The time for the medicine to be fully eliminated from the body is based on these component half-lives.


Q: Are there any specific foods or drinks I should avoid while on Angenta?

The most significant precaution mentioned in the regulatory text is the risk of enhanced effects when taken with alcohol, which can increase sedation. While no specific non-alcoholic drinks or foods are universally prohibited, general caution with substances that affect the central nervous system is usually advised.


Q: Can Angenta be taken on an empty stomach, or must it be with food?

Official administration instructions state that the tablets are film-coated and should be swallowed whole with water. The regulatory documentation is typically silent on the exact timing relative to meals. Any specific instructions regarding timing with meals should be followed as directed by a healthcare provider.


Q: Do Angenta's side effects usually lessen over time?

Official safety data indicates that the most common side effects, such as dry mouth or restlessness, are generally described as transient. This description suggests that side effects may improve over time as the body adjusts to the medication.


Q: Does Angenta interact with any common anti-depressants?

Yes, Angenta is strictly contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs). Due to the risk of serious reaction, a specific washout period (up to 14 days, depending on the MAOI type) is required after stopping an MAOI before Angenta can be started.


Q: How quickly should I notice the effects of Angenta after starting it?

Pharmacokinetic data shows that the active ingredients reach their maximal concentration in the blood approximately 4 hours after administration. While clinical trial data suggests that some effects may be noticed relatively quickly, full therapeutic benefit may take several weeks to be fully established.


Q: Is Angenta a generic drug, or is it only available under the brand name?

Angenta is a brand name for a fixed-dose combination containing the active ingredients flupentixol and melitracen. Generic fixed-dose formulations containing these two compounds have been approved and marketed in certain regions after meeting bioequivalence standards.


Q: Can Angenta be crushed or dissolved for easier consumption?

Official regulatory instructions explicitly state that the film-coated tablets should be swallowed whole with water. Altering the tablet (crushing, splitting, or dissolving) is generally not recommended, as it could potentially interfere with how the medicine is absorbed by the body.


Q: Are there specific tests a doctor performs before prescribing Angenta?

While the labeling does not mandate specific routine tests, it lists several conditions that require caution (such as certain cardiac problems or liver disease). The presence of pre-existing conditions often necessitates assessment or monitoring, which may include tests, to ensure the medicine is appropriate for the individual.


Q: Is it safe to drive while taking Angenta?

Because Angenta can cause side effects like drowsiness or dizziness, official warnings advise caution when performing skilled tasks. Individuals are advised to determine how the medication affects their reactions and alertness before engaging in activities like driving or operating machinery.


Q: Why is the mechanism of action of Angenta considered unique?

Angenta is distinguished by its unique status as a fixed-dose combination of two different types of agents: an antidepressant (melitracen) and an anxiolytic (flupentixol). This dual-action approach is intended to provide a balanced therapeutic effect that addresses both low mood and associated tension simultaneously.


Q: Is Angenta safe for people with a history of kidney issues?

Official regulatory information notes that limited data is available regarding the use of its components in patients with kidney (renal) disease. Caution is generally advised, and individual adjustments may be considered by the prescribing clinician for individuals with impaired kidney function.


Q: Is a sudden headache a common side effect of Angenta?

A mild headache is listed among the most frequently reported adverse events in clinical trials associated with Angenta use. These occurrences are usually described as mild to moderate in intensity and are generally transient.


Q: Does Angenta affect blood sugar levels?

One of the active components, Melitracen, belongs to the tricyclic antidepressant (TCA) class. This class of medicine has been associated with potential changes in glucose homeostasis (blood sugar levels) in some studies, which may be relevant for individuals with diabetes.


Q: How does Angenta compare to a placebo in clinical trials?

Clinical studies indicate that the proportion of patients treated with Angenta who achieved a significant clinical improvement (based on pre-defined measures) was statistically higher compared to the group receiving a placebo. This suggests the medicine is effective compared to an inert substance.

How should Angenta be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory information defines the mandatory conditions for storing and disposing of Angenta to maintain its quality and safety.

Storage Requirement Official Classification
Temperature Store at controlled room temperature (20 C to 25 C).
Protection Keep in the original container, tightly closed, protected from both moisture and light.
Prohibited Do not freeze the medicine.
Safety Keep Angenta out of the sight and reach of children.

Unused or expired Angenta must be handled according to specific pharmaceutical waste guidelines. The labeling instructs users not to dispose of the medicine through household trash or wastewater (e.g., flushing down the toilet). Instead, the product must be returned to a pharmacy or an authorized drug take-back site for disposal in accordance with local environmental protection regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Angenta found in:

A-Z Index: